NSW CTP medication rules and guidelines

Expert overview of SIRA medication governance in motor accident claims for professional insurers

Published 3 April 2026

Introduction

New South Wales' Compulsory Third Party (CTP) insurance scheme is regulated by the State Insurance Regulatory Authority (SIRA) and governed by the Motor Accident Injuries Act 2017 (MAI Act). Medication governance in CTP claims presents specific challenges and opportunities, as claimants frequently sustain acute injuries triggering complex medication management needs. For professional indemnity insurers managing CTP claims in NSW, understanding the regulatory framework and best practice medication governance is essential.

This article provides a specialist overview of medication rules and guidelines applicable to NSW CTP claims, with focus on practical application for insurers and claims managers.

Legislative and Regulatory Framework

The Motor Accident Injuries Act 2017 establishes the legal framework for CTP claims in NSW. This legislation applies a "reasonable and necessary" test for treatment expenses, which extends to medications. Treatments and medications are considered compensable where they are "reasonable and necessary" for the treatment and recovery of the claimant from the motor accident injury.

SIRA guidelines and information materials provide additional guidance on claims assessment and treatment authorization. While SIRA does not issue prescriptive medication protocols, it does establish principles around treatment reasonableness that apply to medications, including:

• Clinical evidence and guideline alignment for medication selection.
• Appropriateness of dose and duration relative to injury severity and recovery expectations.
• Consideration of functional recovery and return-to-work objectives in medication selection.
• Monitoring and review of medication efficacy and safety in ongoing claims.

SIRA's Guidance on Treatment Authorization and Costs

SIRA has issued guidance on treatment cost assessment within the reasonable and necessary framework. While medications are not subject to the same pathway authorization requirements as some other treatments, they remain subject to the reasonableness and necessity assessment. This means that insurer authorization or approval of medications, where required by policy or claims management protocols, should be informed by clinical evidence and guidance.

Prescribing Standards and Evidence-Based Practice

Prescribers in NSW are expected to follow the Therapeutic Guidelines and the Australian Medicines Handbook as primary references for evidence-based prescribing. For motor accident claimants, several medication-related issues warrant specific attention by insurers.

Pain Management and Analgesic Prescribing

Acute injury pain is a primary driver of medication use in early CTP claims. Current best practice emphasizes multimodal pain management combining pharmacological and non-pharmacological interventions. For analgesic prescribing in CTP claims, best practice includes:

• Early use of non-opioid analgesics (paracetamol, NSAIDs) where clinically appropriate.
• Application of opioid analgesics only where non-opioid therapy is insufficient, with documented clinical justification.
• Short-term opioid prescribing (typically 2-4 weeks) for acute pain with regular review and deprescribing planning.
• Integration of analgesic therapy with rehabilitation and mobilization to facilitate functional recovery.

Prolonged opioid use in motor accident claims is associated with increased medication dependence risk and may impair functional recovery. Insurers should expect practitioners to transition from opioid to non-opioid therapy as the acute phase resolves.

Muscle Relaxants and Spasticity Management

Muscle relaxants such as diazepam and other benzodiazepines are sometimes prescribed for acute muscle spasm following motor accident injury. However, current guidelines recommend limiting benzodiazepine prescribing to short-term use (typically 2-4 weeks) due to dependence risk, sedation, and impact on functional recovery. Alternative approaches to spasticity management, such as physiotherapy and exercise, should be prioritized.

Psychotropic Medications and Mental Health Support

Motor accident injury frequently results in anxiety, depression, or post-traumatic stress disorder (PTSD). Selective serotonin reuptake inhibitors (SSRIs) are considered first-line pharmacological treatment for depression and anxiety. Psychotropic medication prescribing should be integrated with psychological interventions such as cognitive-behavioral therapy.

Insurers should expect that psychotropic prescribing is accompanied by mental health support and that functional impact of psychotropic medications (particularly sedation or cognitive effects) is documented and considered in return-to-work planning.

Benzodiazepine and Z-Drug Prescribing

Benzodiazepines and related substances (Z-drugs) warrant particular scrutiny in CTP claims due to dependence risk and potential impedance of functional recovery. SIRA guidelines emphasize the importance of evidence-based treatment selection. For benzodiazepine prescribing in CTP claims:

• Initial prescribing should be time-limited (2-4 weeks maximum) with explicit deprescribing plan.
• Regular clinical review is essential, particularly where initial prescription period is exceeded.
• Alternative interventions (psychological therapy, rehabilitation, sleep hygiene support) should be prioritized alongside or instead of pharmacological therapy.
• Risk of dependence should be documented, particularly for claimants with personal or family history of substance use.

Prolonged benzodiazepine use in CTP claims presents a governance challenge for insurers, as such use may not align with the recovery trajectory typical of motor accident injuries and may complicate rehabilitation planning.

Pharmacy Services and Medication Access

Community pharmacists in NSW play an important role in medication counseling and access support for CTP claimants. Key pharmacy services relevant to CTP claims include:

Insurers managing CTP claims may benefit from engaging pharmacy services in the following scenarios:

• Complex polypharmacy requiring medication rationalization or deprescribing.
• Long-term medication use extending beyond typical acute recovery timeframes.
• Benzodiazepine or opioid dependence risk requiring specialist deprescribing support.
• Medication adherence issues impacting rehabilitation progress.

Schedule 8 (Controlled Drugs) Prescribing

Schedule 8 substances in NSW include opioids and other controlled medications. Prescribing of Schedule 8 substances is subject to NSW-specific regulatory requirements including prescription form requirements and record-keeping. In CTP claims, Schedule 8 prescribing should be:

• Time-limited with clear clinical justification documented.
• Subject to regular review by the prescriber, with assessment of continued necessity and efficacy.
• Accompanied by risk screening for dependence, particularly for claimants with personal or family history of substance use disorder.
• Integrated with rehabilitation planning and physical therapy to promote functional recovery.

Motor accident injuries often resolve within 12 months. Prolonged Schedule 8 prescribing extending beyond typical recovery timeframes warrants insurer review and consideration of independent medication assessment.

Return to Work and Medication Implications

A key objective of CTP claims management is facilitating return to work. Medication selection and management should be considered in relation to return-to-work feasibility. Medications that impair alertness, cognition, or motor function may impact ability to return to work, particularly in safety-critical roles.

Insurers should expect that treating practitioners document:

• Functional impact of medications, particularly any effects on alertness, cognition, or motor control.
• Consideration of medication adjustments where functional impairment affects work capacity.
• Coordination between medication management and rehabilitation planning.
• Regular review of ongoing medication necessity as the claimant's functional capacity improves.

Independent Medication Review in CTP Claims

Independent medication reviews by specialist pharmacists can provide valuable insight into medication appropriateness, dependence risk, and functional implications in complex CTP claims. Medication reviews are particularly valuable in scenarios including:

• Complex polypharmacy requiring rationalization or deprescribing.
• Prolonged opioid or benzodiazepine prescribing beyond typical acute recovery timeframes.
• Medication-related functional impairment affecting return-to-work capacity.
• Disputes regarding medication necessity or appropriateness.
• Transition from acute to long-term medication management in ongoing claims.

Practical Considerations for CTP Insurers

Best practice medication governance in NSW CTP claims should include:

• Early assessment: Review medication profile in early claims assessment, identifying any concerning prescribing patterns or polypharmacy issues.
• Communication: Document all medication-related discussions with treating practitioners and claimants, maintaining clear records of clinical reasoning for medication-related decisions.
• Rehabilitation coordination: Ensure medication management is coordinated with rehabilitation planning to support functional recovery and return to work.
• Specialist input: Engage pain specialists, psychiatrists, or other medical specialists where medication-related concerns require expert assessment.

Recent Developments and Future Trends

NSW CTP regulation continues to evolve, with increasing focus on opioid stewardship, mental health integration, and early intervention approaches. Insurers should remain aware of regulatory updates from SIRA and adapt medication governance approaches accordingly. The growing availability of independent medication review services with specific CTP experience provides insurers with enhanced capacity to manage medication-related risk effectively.